These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28749424)

  • 1. Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.
    Kalimuthu S; Jeong JH; Oh JM; Ahn BC
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of molecular imaging in drug discovery and development process.
    Ahn BC
    Curr Pharm Biotechnol; 2011 Apr; 12(4):459-68. PubMed ID: 21342108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive molecular imaging using reporter genes.
    Brader P; Serganova I; Blasberg RG
    J Nucl Med; 2013 Feb; 54(2):167-72. PubMed ID: 23318292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model.
    Robertson R; Germanos MS; Manfredi MG; Smith PG; Silva MD
    J Nucl Med; 2011 Nov; 52(11):1764-9. PubMed ID: 21994410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies.
    Gangadaran P; Ahn BC
    Front Immunol; 2017; 8():1090. PubMed ID: 28955332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging in drug development.
    Willmann JK; van Bruggen N; Dinkelborg LM; Gambhir SS
    Nat Rev Drug Discov; 2008 Jul; 7(7):591-607. PubMed ID: 18591980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.
    Ayers EC; Fardin S; Gholami S; Alavi A; Mato AR
    PET Clin; 2016 Jul; 11(3):209-18. PubMed ID: 27321026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.
    England CG; Rui L; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):517-532. PubMed ID: 27844106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.
    Visvikis D; Ell PJ
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S106-16. PubMed ID: 12748830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
    Li F; Zhu HY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant lymphoma].
    Okamoto R
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of pre-clinical PET imaging for drug development].
    Tsukada H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):231-7. PubMed ID: 22256612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical and magnetic resonance imaging as complementary modalities in drug discovery.
    Sandanaraj BS; Kneuer R; Beckmann N
    Future Med Chem; 2010 Mar; 2(3):317-37. PubMed ID: 21426169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET/CT in lymphoma: two decades of experience.
    Alvarez Páez AM; Nogueiras Alonso JM; Serena Puig A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):340-9. PubMed ID: 22841459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pivotal role of multimodality reporter sensors in drug discovery: from cell based assays to real time molecular imaging.
    Ray P
    Curr Pharm Biotechnol; 2011 Apr; 12(4):539-46. PubMed ID: 21342103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of spectral molecular imaging: potential and challenges.
    Anderson NG; Butler AP
    Contrast Media Mol Imaging; 2014; 9(1):3-12. PubMed ID: 24470290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.